NVVE exhibits extreme financial distress, anchored by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. The company suffers from negative equity (Price/Book of -0.27) and catastrophic profitability metrics, including an ROE of -5084.87% and negative gross margins. A devastating 98.3% decline in share price over the last year, coupled with a 52-week high of $142.00 versus a current price of $0.67, suggests a total collapse in investor confidence. The lack of an Altman Z-Score and Graham Number further confirms that the company does not meet the minimum thresholds for solvency or defensive valuation.